Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Authors
Keywords
-
Journal
LANCET
Volume 399, Issue 10326, Pages 729-740
Publisher
Elsevier BV
Online
2022-01-24
DOI
10.1016/s0140-6736(22)00010-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data
- (2021) Antonia M. Joussen et al. EYE
- Non-adherence or non-persistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review
- (2020) Mali Okada et al. OPHTHALMOLOGY
- Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
- (2020) Jayashree Sahni et al. JAMA Ophthalmology
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
- (2020) Arshad M. Khanani et al. JAMA Ophthalmology
- THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES
- (2020) Jeffrey S. Heier et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration
- (2019) Mark C. Gillies et al. JAMA Ophthalmology
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
- (2019) Pravin U. Dugel et al. OPHTHALMOLOGY
- Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
- (2019) Michèle Augsburger et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration
- (2018) Rufino Silva et al. OPHTHALMOLOGY
- Age-related macular degeneration
- (2018) Paul Mitchell et al. LANCET
- Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- (2016) Jörg T Regula et al. EMBO Molecular Medicine
- Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study
- (2015) Jonathan L. Prenner et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration
- (2015) Charles C. Wykoff et al. OPHTHALMOLOGY
- Molecular pathogenesis of retinal and choroidal vascular diseases
- (2015) Peter A. Campochiaro PROGRESS IN RETINAL AND EYE RESEARCH
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
- (2014) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
- (2013) Brandon G. Busbee et al. OPHTHALMOLOGY
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- (2012) Michael A. Singer et al. OPHTHALMOLOGY
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
- (2011) W. Schaefer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
- (2008) Carl D. Regillo et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now